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Background: The current vaccines for porcine reproductive and respiratory syndrome virus (PRRSV) have failed to
provide broad protection against infection by various strains of PRRSV. Porcine Interleukin-4 (pIL-4) plays an important
role in the regulation of the immune response and has been used previously as an immunological adjuvant. The
objective of this study was to construct a recombinant PRRSV expressing pIL-4 and to evaluate the immune
response of the recombinant virus in piglets.
Methods: The pIL-4 gene was inserted in the PRRSV (CH-1R strain) infectious clone by overlap PCR. Indirect
immunofluorescence assay (IFA) and Western blotting were used to confirm the recombinant virus. The stability
of the recombinant virus was assessed by DNA sequencing and IFA after 15 passages in vitro. Recombinant virus
was injected into pigs and efficacy of immune protection was evaluated in comparison with the parental virus.
Results: The recombinant virus (CH-1R/pIL-4) was successfully rescued and shown to have similar growth kinetics as the
parental virus. The recombinant virus was stable for 15 passages in cell culture. Pigs vaccinated with CH-1R/pIL-4
produced a similar humoral response to the response elicited by parental virus, but IL-4 level in the supernatant of PBMCs
from pigs vaccinated with CH-1R/pIL-4 was significantly higher than the parent virus at 28 days post-immunization (DPI).
Flow cytometric (FCM) analysis showed that the percentage of CD4+CD8+ double positive T (DPT) cells in the CH-1R/pIL-4
vaccinated group was significantly higher than the parental virus at 3 and 7 Days Post-Challenge (DPC), and the IL-4 level
in the blood significantly increased at 7 DPC. However, the viral load and histopathology did not show significant
difference between the two groups.
Conclusions: A recombinant PRRSV expressing porcine IL-4 was rescued and it remained genetically stable in vitro. The
recombinant virus induced higher DPT ratios and IL-4 levels in the blood after HP-PRRSV challenge compared to the
parental virus in piglets. However, it did not significantly improve protection efficacy of PRRSV vaccine.
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Porcine reproductive and respiratory syndrome (PRRS) is
characterized by clinical signs of reproductive failure in
pregnant sows and respiratory distress in pigs of all ages
[1]. Since it’s first reported in 1987, PRRS has become a
severe threat to the swine industry worldwide [2]. The* Correspondence: wangchengbao@nwsuaf.edu.cn; aci139@sina.com;
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respiratory syndrome virus (PRRSV) was successfully
isolated in EU and USA in 1991 and 1992, respectively
[3, 4]. Surprisingly, the two genotypes showed sequence
identity of only 60 % and a high degree of antigenic vari-
ation [5, 6]. In June 2006, an unparalleled, large-scale,
PRRS outbreak occurred in China, leading to widespread
infection which continues to be a serious problem today.
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positive-sense RNA genome of approximately 15 kb in
length [10]. The genome contains a cap structure at the 5′
end, a poly (A) tail at the 3′ end, and 5′ and 3′
un-translated regions (UTRs). Two overlapping open read-
ing frames (ORF 1a and ORF 1b) occupy two thirds of the
genome at the 5′ end. These ORFs encode two large
polyproteins that undergoes co-translational and post-
translational processing to give rise to at least 14 non-
structural proteins (nsps). ORFs 2–7 code for viral
structural proteins GP2, E, GP3, GP4, GP5a, GP5, M, and
N, respectively [11–14]. According to the recently accepted
replication model for viruses of the order Nidovirales ,
PRRSV and other arteriviruses synthesize a nested set of
subgenomic (sg) mRNAs as a mechanism to regulate the
expression of structural or accessory proteins [15]. Base
pair interactions between the transcription-regulating
sequences (TRSs) located at the 3′ end of the leader
sequence and the complement of body TRSs presented
upstream of each gene, have been shown to be essential for
this process [16].
It is well recognized that due to the genetic diversity of
the PRRSV strains, none of the current vaccines can com-
pletely protect against PRRSV infections. For PRRSV vac-
cines, the efficacy of protective immunity is usually assessed
by the reduction in viremia after challenge with a virulent
virus [17, 18]. Sufficient amount of neutralizing antibodies
may prevent the infection, but cannot clear the virus in
blood during the course of the infection. Therefore, vaccine
immunity relies on the induction of the protective cell-
medicated immune responses in prevention against PRRSV
infection [19, 20]. CD4+CD8+ double positive T (DPT) cells
are the main effectors of adaptive cellular immune response
and essential to clear viral infection [21]. IFN-γ secreting
cells are mainly DPT cells and whose levels are correlated
with the host ability prevent PRRSV infection [22].
It is clear that there is an urgent need for a safe and more
effective PRRSV vaccine. In order to increase the efficacy of
the vaccine, an alternative approach is to co-deliverFig. 1 Schematic diagram of the recombinant plasmid (pBAC-CH-1R/pIL-4)
the 3′-UTR of the attenuated PRRSV infectious clone (pBAC-CH-1R). It exhib
transcription regulation sequence for ORF6 (TRS6)cytokines to up-regulate the immune response of vaccine
antigens. Interleukin-4 (IL-4) is a pleiotropic cytokine and
has been used as an adjuvant to enhance immune response
of PRRSV vaccines [23, 24]. In addition, IL-4 may posi-
tively modulate vaccination mediated clearance of
PRRSV [22, 25]. In this study, porcine Interleukin-4
(pIL-4) gene was inserted between the N gene and the
3′-UTR of a live attenuated PRRSV infectious clone,
along with a copy of the transcription regulating se-
quence for ORF6 (TRS6), to create a recombinant
PRRSV. The growth characterization and genetic stabil-
ity of the recombinant virus was first analyzed in vitro.
Further, recombinant virus was injected into piglets to
evaluate its potential role for improving vaccine efficacy
in protection against HP-PRRSV infection.Results
Rescue of recombinant virus harboring pIL-4
The recombinant plasmid pBAC-CH-1R/pIL-4 (Fig. 1)
was constructed according to the primers as shown in
Table 1. The recombinant virus CH-1R/pIL-4 was suc-
cessfully rescued after transfecting pBAC-CH-1R/pIL-4
plasmid into Marc-145 cells. CPE were markedly ob-
served after 3 days post-transfection (data not shown),
supernatants were then harvested and passaged 3
times in Marc-145 cells.
The presence of recombinant PRRSV was identified by
indirect immunofluorescence assay (IFA) and western
blotting using the PRRSV N-specific antibody (6D10).
Expression of pIL-4 was confirmed using a goat anti-pIL-4
polyclonal Ab. As shown in Fig. 2a, the presence of the
virus was confirmed by the visualization of red fluores-
cence, and pIL-4 with green fluorescence. Western blot-
ting was used to verify protein expression of N and IL-4
(Fig. 2b).
As expected, pIL-4 expression via an additional TRS did
not influence the growth characteristics of the virus. As
shown in Fig. 2c, growth rate and maximum titer of the. The porcine IL-4 (pIL-4) gene was inserted between the N gene and
ited expression as a separate sub-genomic RNA with a copy of the
Table 1 Primers used for construction and identification of recombinant PRRSV infectious clones






The italics in the sequence denote the restriction enzyme sites (Asis I, Mlu I)
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virus. Titers peaked at 48 h post infection (hpi) for both
viruses.
The expression of pIL-4 was further analyzed by deter-
mining the accumulation kinetics of pIL-4 in the super-
natant of infected Marc-145 cells. The concentration of
IL-4 was 300 pg/mL at 24 hpi, and it reached the maximum
concentration of 800 pg/mL at 48 hpi (Fig. 2d).
Genetic stability testing
The recombinant virus was serially passaged in Marc-
145 cells for 15 times to examine the genetic stability of
pIL-4 in the virus over time. Viral RNA was isolatedFig. 2 Characterization of recombinant PRRSV expression of the pIL-4 gene in
cells infected with parental virus or recombinant virus. Original magnification
Marc-145 cells infected with recombinant virus and parental virus. c Grow
cells. d Kinetics of pIL-4 accumulation in the supernatants of Marc-145 ce
control. Data are represented as the mean of three independent experimfrom cells after passage 5, 10 and 15 post-infection with
recombinant virus. The presence of the pIL-4 gene in
the viral genome was confirmed using RT-PCR. Unex-
pected gene insertion, deletion and mutation were ruled
out by sequencing (data not shown).
Humoral immune responses
The host humoral immune response was assessed in pigs at
various time-points (Fig. 3a). The antibody titers of the pigs
in the two vaccinated groups showed similar trend and they
could be initially detected at 21 DPI. Titers significantly
increased at 7 through 21 DPC and then dropped at 28
DPC. Antibodies for the challenged (non-vaccinated)Marc-145 cells. a IFA detection of pIL-4 and N expression in Marc-145
200×. b Western blot detection of pIL-4 and N protein in cell lysates of
th curves of the recombinant and the parental virus in Marc-145
lls infected with the recombinant virus vs. parental virus or mock
ents
Fig. 3 Humoral and cell-mediated immunity in pigs infected with the recombinant and the parental virus. a PRRSV-specific serum antibodies were
measured with the IDEXX HerdChek® PRRSV ELISA 2XR Kit. S/P ratios of greater than 0.4 are considered positive. S/P = (Sample A (650)-Negative
Control) / (Positive Control- Negative Control). Parental and recombinant virus groups were compared to the challenged control group. **denotes
p < 0.01; *** represents p < 0.001. b PBMCs were collected from the piglets stimulated with purified PRRS virions. PHA was the positive control.
After 72 h of stimulation, the cells were treated with WST-8 for 2 h and the OD450 values were determined to calculate the stimulation index (SI).
IFN-γ(c) and IL-4 (d) concentrations in the supernatants of PBMC cultures were tested after 72 h of stimulation using commercial ELISA Kits.
*indicates p < 0.05. Data represent the mean ± SD of five pigs from each group
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were markedly increased by 21 DPC and then dropped at
28 DPC. Virus titers were significantly higher at 7 DPC in
challenged unvaccinated group than in the groups vacci-
nated with parental or recombinant virus (p < 0.01,
p < 0.001, respectively). No seroconversion was evident in
the mock group.
T lymphocyte proliferation assay
Purified PRRSV CH-1R antigen was used as stimulator
to perform lymphocyte proliferation assay. As shown in
Fig. 3b, the CH-1R/pIL-4 vaccinated group stimulated
PRRSV-specific lymphocyte proliferative response which
was similar to the response of the CH-1R vaccinated
group at 28 DPI and 7 DPC.
We further monitored the temporal expression of
INF-γ and IL-4 in PBMCs after stimulation with purified
PRRSV. As shown in Fig. 3c, IFN-γ expression in
PBMCs from pigs in the CH-1R/pIL-4 group was signifi-
cantly lower than expression in the CH-1R vaccinated
group at 7 DPC (p < 0.05). However, IL-4 expression was
significantly higher in the CH-1R/pIL-4 group than in
the CH-1R group at 28 DPI (p < 0.05) (Fig. 3d).T lymphocyte phenotypic analysis
The percentages of CD3+ single positive T (SPT) cells,
CD4+ SPT cells, CD8+ SPT cells, and CD4+ CD8+ double
positive T (DPT) cells in peripheral blood were measured
by flow cytometric (FCM) analysis. The percentage of CD3
+ SPT cell subpopulations remained relatively stable in all
groups during the experimental period. There was no sig-
nificant change in the levels of the DPT cells in either of
the immunized groups during vaccination period, however,
the numbers of DPT cells in the recombinant virus group
were markedly higher at 3 and 7 DPC compared with the
parental virus group (p < 0.05). Interestingly, the DPT cells
in the challenged control group rapidly decreased after
challenge, returned to normal by 21 DPC. Table 2 shows
the complete results of the FCM analysis.
Cytokine responses
At 14 DPI and 0, 7, 14, 21 and 28 DPC, the sera of the
pigs were collected to detect the production of IFN-γ
and IL-4. As shown in Fig. 4a, IFN-γ expression in sera
was not significantly different between two immunized
groups during experimental period. However, mean IL-4
level in the serum of group vaccinated with recombinant
Table 2 Flow cytometric analysis for proportion of T lymphocyte subpopulations in peripheral blood of pigs
Marker 14a 28a 3b 7b 14b 21b 28b
CD3+
Group1 56.4 ± 4.5 61.1 ± 8.6 65.6 ± 3.6 66.4 ± 5.0 57.7 ± 4.7 58.7 ± 7.0 69.8 ± 7.9
Group2 51.9 ± 5.6 49.0 ± 6.7 53.9 ± 6.8 59.9 ± 3.9 51.8 ± 8.4 54.4 ± 5.8 58 ± 6.6
Group3 52.7 ± 3.9 49.8 ± 10.9 44.76 ± 6.3 59.6 ± 8.8 61.1 ± 5.2 57.2 ± 7.3 51.4 ± 8.3
Group4 50.8 ± 2.1 49.8 ± 6.4 48.3 ± 7.0 52.6 ± 8.7 51.8 ± 10.7 50.6 ± 9.7 52.4 ± 6.8
CD4+
Group1 18.6 ± 3.4 15 ± 4.1 9.7 ± 3.8 4.6 ± 0.3 4.3 ± 4.2 1.9 ± 0.6 4.1 ± 1.2
Group2 17 ± 1.2 16.5 ± 8.4 5.9 ± 2.9 5.2 ± 5.4 6.3 ± 2.3 1.33 ± 0.9 4.2 ± 2.5
Group3 28.7 ± 0.2 24.9 ± 8.2 11.6 ± 5.5 3.1 ± 1.5 8.0 ± 5.3 20 ± 6.3 22.7 ± 2.2
Group4 23.6 ± 4.3 30.7 ± 5.4 26.5 ± 3.7 32.4 ± 0.2 26.3 ± 3.5 19.6 ± 2.8 23.1 ± 3.3
CD8+
Group1 30.3 ± 5.3 33.3 ± 8.1 27.6 ± 6.5 64.8 ± 8.2 50.7 ± 6.6 53.0 ± 9.2 46 ± 0.2
Group2 27.5 ± 5.4 35.5 ± 7.3 26.4 ± 3.0 58.8 ± 9.1 48.6 ± 2.0 51.8 ± 11.2 50.1 ± 4.7
Group3 28.0 ± 4.5 29.1 ± 7.5 13.5 ± 2.1 24.5 ± 6.2 29.7 ± 9.5 38.8 ± 3.2 30 ± 3.6
Group4 29.7 ± 6.4 32.7 ± 3.0 29.3 ± 2.6 29.5 ± 8.7 30.2 ± 8.9 32.4 ± 3.3 36.7 ± 0.5
CD4+CD8+
Group1 29.4 ± 7.8 23.9 ± 8.6 32.9 ± 3.1* 39.1 ± 2.6* 28.3 ± 7.1 25.4 ± 6.5 31.4 ± 7.7
Group2 30.5 ± 4.2 21.7 ± 9.7 18.3 ± 5.2 26.4 ± 4.5 17.2 ± 7.4 26.0 ± 7.9 29.5 ± 3.8
Group3 18.9 ± 0.1 18.5 ± 7.0 8.7 ± 3.0 7 ± 5.7 13.2 ± 1.2 19.2 ± 6.9 18.1 ± 5.3
Group4 20.5 ± 4.3 22.8 ± 3.1 28 ± 4.8 26.4 ± 10.2 25.7 ± 8.0 23.5 ± 6.5 28.9 ± 4.1
Results are expressed as mean (%) ± SD. Group 1: CH-1R/pIL-4 + Challenged; Group 2: CH-1R + Challenged; Group 3: Challenged; Group 4: Mock. *p < 0.05
aDays post- immunization (DPI); bDays post-challenge (DPC)
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group at 7 DPC (p < 0.01) (Fig. 4b).
Observation of clinical signs and rectal temperature testing
All of the pigs presented with a high fever (≥40 °C) after
challenge. Rectal temperatures from the challenged group
increased rapidly at 2 DPC and remained above 41 °C
from 3 to 12 DPC, before returning to normal at 14 DPC.
Two immunized groups also showed similar fever pattern,
but the overall rectal temperatures were relatively low and
of shorter duration. There was no significant difference inFig. 4 Concentrations of Th1-type (IFN-γ) and Th2-type (IL-4) cytokines in t
group at different time points and quantitative ELISA kits were used to d
compared to the recombinant vaccinated group and * denotes p < 0.05.fever magnitude and duration between groups. No rectal
temperature variations were observed in the mock group
during the experimental period (Fig. 5a).
The challenged group showed obvious clinical signs of
infection, including dyspnea, severe lethargy, cough, and
anorexia after challenge. Two pigs showed typical “blue
ears” and died at 7 and 10 DPC. Similar clinical signs
were observed in the two immunized groups following
challenge, but the signs were milder and of shorter
duration relative to the unimmunized pigs. The scores
of clinical signs between two immunized groups werehe sera of pigs. Serum samples were collected from five pigs in each
etect level of IFN-γ (a) or IL-4 (b). The CH-1R vaccinated group was
Data represent the mean ± SD of five pigs from each group
Fig. 5 Rectal temperatures, viremia assessment and pathological examination of five pigs in each group challenged with HP-PRRSV (HuN4).
a Rectal temperatures were recorded after challenge; b Viral RNA in serum was detected at 0, 7, 10, 14, 21 and 28 DPC; c The pigs were
sacrificed at 28 DPC, and lung tissue samples were examined using hematoxylin and eosin staining (H&E). Data are shown as mean ± SD for
five pigs per group; Scale bar: 200 μm
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cantly lower than that in the challenged control group
(p < 0.05) (Table 3).Viremia assessment
At 0, 7, 14, 21 and 28 DPC, the blood samples of the
pigs were collected and the viral loads in the sera were
investigated. As shown in Fig. 5b, all of the challenged
groups developed highest degree of viremia at 7 DPC,
gradually dropped at 14 DPC and then returned to
normal. The two immunized groups exhibited slightly
less viremia than the un-immunized challenge group,
but no significant difference was observed (p > 0.05).Table 3 The scores of clinical signs after challenge and lung
lesions recorded at 28 DPCa




CH-1R/pIL-4 + Challenged 3.9 ± 0.18B 21.5 ± 3.32B
CH-1R + Challenged 3.4 ± 0.27B 23.6 ± 5.57B
Challenged 5.6 ± 1.58A 51.2 ± 8.33A
Mock 3 ± 0.00B 6.67 ± 0.58C
aWithin each column, the different letters (A, B, C) represent the values
significantly different (p < 0.05)
bScores of clinical sign were expressed as the sum of daily observations of all
clinical signs
cPercentage of the entire lung affected by pneumoniaPathological examination
On histological examination, lung lesions of pigs in the
challenged group exhibited alveolar epithelial cell prolif-
eration and extensive infiltration of inflammatory cells.
However, the interstitial pneumonitis observed in the
CH-1R/pIL-4 or CH-1R vaccinated groups were milder
than that of un-immunized challenged group at 28 DPC.
The mock group was normal (Fig. 5c).Discussion
The non-essential regions of the PRRSV nsp2 gene have
been utilized previously as an insertion site for expressing
a foreign gene [26–31], but stability of the recombinant
virus was a concern [32]. As a potential remedy to this
problem, foreign gene was inserted between PRRSV
ORF1b and ORF2a, along with a copy of TRS. This ap-
proach had particular advantage of minimizing the effects
of expression and post-translational modification of viral
proteins [33], and a series of recombinant PRRS viruses
have been constructed using this approach [33–37]. In this
study, the pIL-4 gene was inserted between N gene and
3′-UTR of a live attenuated PRRSV infectious clone using
a similar strategy. Both recombinant virus and parental
virus exhibited similar virus titers after growth in Marc-
145 cells, and this pattern was critical for recombinant
vaccine development [38].
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enhanced the protective immune response of pigs and
improved the efficacy of the MLV in preventing PRRS dis-
ease [23], and pIL-4 can enhance immunogenicity of the
PRRSV ORF5 gene vaccine [24]. Conversely, however, pigs
that received PRRSV ORF7 DNA vaccine plus pIL-4-
encoded plasmids did not develop any improved humoral
and cellular immune responses [39]. In present study, re-
combinant virus expressing pIL-4 did not significantly en-
hance the protective immune response after vaccination.
Thus, observations on the adjuvant effect of pIL-4 on
PRRSV vaccine were inconsistent, which may be related to
the species. Porcine IL-4 cannot be used as immunological
adjuvant since it was reported that IL-4 plays a different
role in pigs than in mice and humans, and porcine IL-4
blocks antibody production and also suppresses antigen-
stimulated proliferation of B cells [40]. Another potential
reason may be attributed to insufficient expression levels
of IL-4 or inefficiency of IL-4 in potentiating anti-PRRSV
immunity in vivo. In the absence of adequate amount, IL-
4 cannot work efficiently as adjuvant to enhance immun-
ity efficacy or prevent PRRSV infection [41]. Thus,
additional studies on IL-4 as an adjuvant are required in
different types of PRRSV vaccine as well as in other veter-
inary vaccines to evaluate its adjuvant property.
In this study, we monitored the percentage of several
T lymphocyte subpopulations in the blood at different
time. Our data showed that the frequency of total CD3+
T subpopulations of pigs from all groups was relatively
stable during experimental period (Table 2). Conversely,
a rapid down-regulation of CD4+CD8+ double positive T
(DPT) cells was observed in the challenged control
group after HP-PRRSV (HuN4) infection, as previously
reported [42, 43]. These results suggest one mechanism
of the PRRSV-mediated delay in initiation of virus-specific
adaptive immunity is by altering frequency of important
lymphocytes early post-infection. In addition, we also ob-
served that DPT cells in the recombinant virus group were
markedly higher than the parental virus group at 3 and 7
DPC. Meanwhile, mean IL-4 level in the serum of group
vaccinated with recombinant virus was significantly higher
than that from parental virus group at 7DPC (Fig. 4b).
IL-4 is a mediator of DPT cells cross-talk leading
towards the development of immunity against an infec-
tious pathogen [44], and IL-4 had a potent positive in-
fluence on the generation of DPT cells originally cloned
from CD4+CD8− T lymphocytes [45, 46]. Our results
also indicated that the higher level of IL-4 may be help-
ful to increase the DPT ratio in the serum.
IL-4 expression has been shown to control macro-
phage inflammatory activities in the pig [40], and IL-4
may positively modulate vaccination mediated clearance
of PRRSV [22, 25]. In this study, there were significantly
higher levels of IL-4 detected in recombinant virusvaccinated pigs in supernatants of PBMCs at 28 DPI
(Fig. 3d), and IL-4 was significantly increased in the sera
of pigs vaccinated with recombinant virus at 7 DPC
(Fig. 4b). However, the viremia did not show significantly
difference compared with parental virus after challenge
(Fig. 5b). It is possible that the role of IL-4 may be strain
dependent, or it may not have a direct correlation in
protecting pigs from HP-PRRSV infection.
IFN-γ is a key cytokine that is associated with host cell-
mediated immunity (CMI) response, which is secreted by
natural killer cells and several different T cell subpopula-
tions [25]. IFN-γ reduces PRRSV infection in porcine al-
veolar macrophages in vitro [47]. A live attenuated PRRSV
vaccine that induced high IFN-γ secreting cell frequencies
protected pigs against viremia [48, 49]. In this study, pig-
lets immunized with CH-1R strain did not produce higher
levels of IFN-γ, conversely, higher levels of IFN-γ were
found in piglets infected with HP-PRRSV HuN4 strain
(Fig. 4a). Nonetheless, CH-1R strain can offer protection
against clinical disease after HP-PRRSV HuN4 infection,
and this observation is consistent with our previously pub-
lished work [50, 51]. Therefore, the role of IFN-γ in the
process of the immune protection to CH-1R vaccination
is not clear and need further investigation.
Conclusions
This is first report to demonstrate the use of PRRSV as a
vector to express porcine IL-4. The pIL-4 gene was stably
expressed and did not affect the replication capability of
the parental virus. The recombinant virus could enhance
the T cells immune response by increasing IL-4 expression
level and DPT cells ratio in the blood of piglets after HP-
PRRSV infection. However, it did not significantly improve
the efficacy of PRRSV vaccine.Materials and methods
Cells and viruses
Marc-145 cells (CCTCC, Wuhan, China) were used for
rescue and passaging of PRRSV. The cells were propa-
gated in Dulbecco’s Modified Eagle’s medium (DMEM)
with 10 % heat-inactivated FBS (Gibco®, USA) at 37 °C
with 5 % CO2. For virus infection and titration, DMEM
supplemented with 3 % FBS was used. HP-PRRSV strain
HuN4 (GenBank: EF635006) was used in this study for
challenge.
Construction of plasmids, transfection and virus passage
A PRRSV infectious clone, pBAC-CH-1R, was constructed
as previously described [52]. The porcine Interleukin-4
(pIL-4) gene (GenBank: HQ236500.1), with a TRS motif
and Asis I/ and Mlu I restriction enzyme sites at the 5′-
and 3′- terminal ends, respectively, was constructed using
fusion PCR. The PCR fragments were digested and
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struct, pBAC-CH-1R/pIL-4 was sequenced to confirm the
presence and correct cloning of the desired pIL-4 gene
sequence (Fig. 1). The primers used for these assays are
shown in Table 1.
The pBAC-CH-1R/pIL-4 plasmid was transfected into
Marc-145 cells as described previously [52]. Cell culture
supernatants were harvested at 4–5 days post transfection
and used to infect fresh Marc-145 cells for virus passage.
Growth kinetics and expression of pIL-4 of recombinant
virus
Marc-145 cells were infected with the recombinant or the
parental virus at a multiplicity of infection (MOI) of 0.01.
200 μL supernatant was collected at 12, 24, 36, 48, 72, 84
and 96 h post infection (hpi) and stored at −70 °C. Viral ti-
tration was determined using the Reed-Muench method.
The expression of pIL-4 was determined using a commer-
cial porcine IL-4 ELISA kit (Cloud-Clone Corp, USA).
Indirect immunofluorescence assay (IFA)
Marc-145 cells grown in 96-well plates were infected
with the recombinant or parental virus preparations
(0.01 MOI) for 36 h. After fixation using 4 % parafor-
maldehyde, cells were washed with PBS and incubated
with 6D10, a monoclonal antibody to PRRSV N protein
(produced in our lab), or a goat anti-porcine IL-4 poly-
clonal Ab (R&D Systems, MN) for 1 h. Cells were then
washed with PBS and incubated for 1 h with a Cy3-
conjugated goat anti-mouse secondary antibody (Jackson
ImmunoResearch Inc, USA) or an Alexa Fluor 488-labeled
donkey anti-goat secondary antibody (Abcam, UK), re-
spectively. Images were taken using a Leica confocal
microscope.
Western Blotting
Marc-145 cells were infected with the recombinant or
parental viruses (0.01 MOI) for 36 h. The cells were then
lysed in RIPA lysis buffer (Beyotime, China). Cell lysates
were electrophoresed on 12 % SDS-PAGE gels and
transferred onto PVDF membranes (Millipore, USA). The
membranes were blocked and incubated for 1 h with
6D10 or a goat anti-porcine IL-4 polyclonal Ab (R&D
Systems, MN), then incubated with HRP-conjugated goat
anti-mouse IgG (Sigma-Aldrich, USA), or HRP-labeled
donkey anti-goat IgG (Sigma-Aldrich), as secondary anti-
bodies, respectively. Immunostained proteins were visual-
ized using ECL Western Blotting Substrate (Beijing Cowin
Bioscience, China).
Genetic stability of the recombinant PRRSV
To investigate whether the inserted pIL-4 gene could be
stably maintained in the recombinant virus, the virus
was serially passaged 15 times in Marc-145 cells. ViralRNA was isolated from cells infected with different
passaged recombinant viruses (P5, P10 and P15) and
RT-PCR was performed using specific primers (Table 1).
PCR products were cloned into the pEASY™-Blunt
Simple Cloning Vector (TransGen Biotech, China) and
the DNA was sequenced.
Animals, vaccination, and HP-PRRSV challenge
Twenty four-week-old piglets were obtained from a
PRRS-free farm in Harbin, China. All piglets were negative
for anti-PRRSV antibodies, as assessed by commercial
ELISA kit (IDEXX, USA) and PRRSV-free in serum by
RT-PCR. Animals were randomly allotted to four groups
and housed separately. Piglets were intramuscularly im-
munized twice with 2 mL (1 × 105.5 TCID50/mL) of re-
combinant virus (group 1) or parental virus (group 2) on
0 and 14 DPI.
All piglets were challenged intranasally with 2 mL HP-
PRRSV (HuN4-F5, 1 × 105.0 TCID50/mL) at 28 DPI, except
those in Group 4, which were given only cell culture
medium (uninfected control). Rectal temperatures were
documented daily after challenge. Pigs were monitored
daily for clinical signs, including dyspnea, lethargy, cough
and anorexia. The pigs were euthanized at 28 days post-
challenge (DPC). The severity of the clinical signs was
evaluated daily after challenge as reported [53]. Briefly,
scores ranged from 1 to 4 were determined for behavior,
respiration and coughing. Score 1, 2 and 3 represents nor-
mal, mild and severe, respectively. Score 4 represents
death. To estimate the severity of pathological lesions,
gross lesions of each lobe were scored and evaluated as
percentage of lung with grossly visible pneumonia [54].
Animal research was conducted under the Animal
Welfare and Ethical Guidelines of the Institutional Animal
Care Committee.
Circulation antibody titration
Sera were collected at 14 and 21 DPI and at 0, 7, 14, 21,
and 28 DPC. PRRSV N-specific antibodies were tested
using a commercial PRRS ELISA kit (IDEXX, USA)
following the manufacturer’s instructions.
T lymphocyte proliferation assay
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from experimental pigs as previously described
[55]. Briefly, The PBMCs were diluted to 5 × 106/mL in
RPMI 1640 supplemented with 10 % FBS and plated in
96-well flat-bottom plates at 100 μL per well in triplicate.
Subsequently, the purified-PRRS virions (20 μg/mL) as
stimulator were added to the cultures, and PHA (5 μg/mL,
Sigma-Aldrich, USA) was used as a positive control. After
incubation for 72 h at 37 °C in 5 % CO2, 10 μL of WST-8
(Cell Counting Kit-8, Beyotime Biotechnology, China) was
added to each well and the cells were incubated for 2 h.
Li et al. Virology Journal  (2015) 12:185 Page 9 of 10At the end of the incubation, the absorbance was deter-
mined at 450 nm. The stimulation index (SI) was calcu-
lated as the ratio of the average optical density (OD)
value of wells containing antigen-stimulated cells to the
average OD value of wells containing cells cultured with
medium alone.
Flow cytometric (FCM) analysis
Flow cytometric (FCM) analysis was performed to in-
vestigate various lymphocyte populations in the blood.
Briefly, 50 μL of anti-coagulated blood sample was
incubated with SPRD-labeled mouse anti-pig CD3ε,
FITC-labeled mouse anti-pig CD4, and PE-labeled
mouse anti-pig CD8 (Southern Biotech, USA), in the
dark for 30 min. 1x RBC lysis buffer (BioLegend, San
Diego, CA, USA) was added to each sample and gently
vortexed immediately for 15 min. Samples were centri-
fuged at 350 × g for 5 min and washed twice with 2 %
FBS, before FCM studies were performed using a BD
Accuri™ C6 flow cytometer (BD Biosciences, San Jose, CA,
USA). Frequencies of lymphocyte populations were deter-
mined from 100,000 events using BD Accuri™ C6 software.
Cytokine assays
Lymphocytes were prepared and stimulated as described
above. After incubation for 72 h, culture supernatants
from PBMCs of piglets were collected and Th1-type
cytokine (IFN-γ) and Th2-type cytokine (IL-4) levels
were assessed using commercial ELISA kits (Cloud-
Clone Corp, USA).
For the detection of IFN-γ and IL-4 production in pigs
at various time-points, sera samples were isolated, and
cytokines concentrations were determined according to
manufacturer’s instructions.
Viremia testing
Total RNA was extracted from sera using Trizol Total
RNA Extraction Kit (Shanghai Sangon Biological Engin-
eering Technology & Services, China), cDNA was syn-
thesized using AMV Reverse Transcriptase XL (TaKaRa,
Japan) with oligo (dT) and Quantitative RT-PCR was
performed as described previously [50].
Histopathological examination
All pigs were euthanized at 28 DPC. Lungs were har-
vested and fixed in 10 % neutral buffered formalin then
stained with hematoxylin and eosin (H&E) for histo-
pathological examination.
Statistical analysis
GraphPad Prism V.5 software (GraphPad Software, La
Jolla, CA, USA) was used for statistical analysis. Results
were considered to be statistically significant when the pvalue was less than 0.05, using one-way analysis of vari-
ance (ANOVA).
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